REGENXBIO Inc. stock steadies after Morgan Stanley conference appearance
Published on 09/17/2026 at 17:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
REGENXBIO Inc. stock (ISIN US75901B1052) is valued at a market capitalization of about USD 522.2 million as of September 17, 2026, positioning the gene therapy specialist as a mid-cap player in the biotechnology sector.
Conference appearance underscores pipeline
REGENXBIO Inc. participated in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, where management discussed the company’s gene therapy pipeline and strategic priorities in a dedicated session at 8:30 a.m. Eastern Time, according to Seeking Alpha on September 16, 2026.
A transcript of the session published on September 16, 2026 confirms that the presentation was part of the broader Morgan Stanley Global Healthcare Conference agenda and focused on clinical development progress and partnering opportunities in gene therapy, as reported by GuruFocus on September 16, 2026.
Market valuation and investor perspective
In the current market context, the market capitalization of approximately USD 522.2 million as of September 17, 2026 reflects the valuation investors assign to REGENXBIO’s portfolio of gene therapy candidates and existing collaborations, based on data from a biotechnology industry overview that lists REGENXBIO Inc. with a market cap of USD 522.164 million and an industry classification of Biotechnology on September 17, 2026, as shown by Yahoo Finance.
For investors, the combination of a mid-cap market capitalization and an active presence at major healthcare conferences such as the Morgan Stanley event on September 16, 2026 highlights both the opportunities and risks typical for clinical-stage biotechnology stocks, where future revenue depends heavily on successful trial outcomes, regulatory approvals and potential licensing or partnership deals.
Stock level and trading venue
REGENXBIO Inc. stock is listed on Nasdaq in United States dollars, and the market capitalization level of about USD 522.2 million as of September 17, 2026 corresponds to a share price in the single-digit USD range on its primary exchange, with trading volumes reflecting typical liquidity for a mid-cap biotechnology issuer.
Key data on REGENXBIO Inc. stock
- Company: REGENXBIO Inc.
- ISIN: US75901B1052
- Ticker: RGNX
- Trading venue: Nasdaq
- Market capitalization: 522.2 million USD (as of September 17, 2026)
- Sector / Industry: Biotechnology
- Index membership: None of the major headline indices such as S&P 500 or Nasdaq 100
